Daniel B. Chambers
University of Alberta
5 Papers
Daniel B. Chambers is an academic researcher from University of Alberta. The author has contributed to research in topics: Fragile X syndrome & Autism. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia
Ziv Gan-Or,Ziv Gan-Or,Naima Bouslam,Nazha Birouk,Alexandra Lissouba,Daniel B. Chambers,Julie Vérièpe,Alaura Androschuk,Sandra B. Laurent,Sandra B. Laurent,Daniel Rochefort,Daniel Rochefort,Dan Spiegelman,Dan Spiegelman,Alexandre Dionne-Laporte,Alexandre Dionne-Laporte,Anna Szuto,Meijiang Liao,Denise A. Figlewicz,Ahmed Bouhouche,Ali Benomar,Mohamed Yahyaoui,Reda Ouazzani,Grace Yoon,Nicolas Dupré,Oksana Suchowersky,Francois V. Bolduc,J. Alex Parker,Patrick A. Dion,Patrick A. Dion,Pierre Drapeau,Guy A. Rouleau,Guy A. Rouleau,Bouchra Ouled Amar Bencheikh,Bouchra Ouled Amar Bencheikh +34 more
TL;DR: Rare homozygous and compound-heterozygous nonsense, missense, frameshift, and splice-site mutations in CAPN1 were identified in all affected individuals, and sequencing in additional family members confirmed the segregation of these mutations with the disease (spastic paraplegia 76).
111
PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.
Catherine H. Choi,Brian P. Schoenfeld,Eliana D. Weisz,Aaron J. Bell,Daniel B. Chambers,Joseph Hinchey,Richard J. Choi,Paul Hinchey,Maria Kollaros,Michael Gertner,Neal J. Ferrick,Allison M. Terlizzi,Nicole L. Yohn,Eric Koenigsberg,David A. Liebelt,R. Suzanne Zukin,Newton H. Woo,Michael R. Tranfaglia,Natalia Louneva,Steven E. Arnold,Steven J. Siegel,Francois V. Bolduc,Thomas V. McDonald,Thomas A. Jongens,Sean M.J. McBride,Sean M.J. McBride +25 more
TL;DR: This work identifies and validates PDE-4 inhibition as potential therapeutic intervention for the treatment of individuals afflicted with FXS and finds that chronic treatment of FXS model mice, in adulthood, also restores the level of mGluR-dependent LTD to that observed in wild-type animals.
57
Insulin signaling is acutely required for long-term memory in Drosophila
Daniel B. Chambers,Alaura Androschuk,Cory Rosenfelt,Steven Langer,Mark Harding,Francois V. Bolduc +5 more
TL;DR: It is found that insulin signaling (InS) is involved in both learning and memory in Drosophila and that InS is acutely required for long-term memory formation in adult flies.
Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models
Catherine H. Choi,Catherine H. Choi,Catherine H. Choi,Brian P. Schoenfeld,Brian P. Schoenfeld,Aaron J. Bell,Aaron J. Bell,Joseph Hinchey,Cory Rosenfelt,Michael Gertner,Sean Campbell,Danielle Emerson,Paul Hinchey,Maria Kollaros,Neal J. Ferrick,Neal J. Ferrick,Daniel B. Chambers,Steven Langer,Steven Sust,Aatika Malik,Allison M. Terlizzi,David A. Liebelt,David Ferreiro,Ali Sharma,Eric Koenigsberg,Richard J. Choi,Natalia Louneva,Steven E. Arnold,Robert E. Featherstone,Steven J. Siegel,R. Suzanne Zukin,Thomas V. McDonald,Francois V. Bolduc,Thomas A. Jongens,Sean M.J. McBride,Sean M.J. McBride +35 more
TL;DR: It is demonstrated that the same three strategies used previously with the potential to be used clinically, lithium treatment, PDE-4 inhibitor treatment or mGluR antagonist treatment can rescue long term memory in the fly model and alter the cAMP signaling pathway in the hippocampus of the mouse model.
Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.
Rachel E. Monyak,Danielle Emerson,Brian P. Schoenfeld,Brian P. Schoenfeld,Xiangzhong Zheng,Daniel B. Chambers,Cory Rosenfelt,Steven Langer,Paul Hinchey,Catherine H. Choi,Catherine H. Choi,Thomas V. McDonald,Francois V. Bolduc,Amita Sehgal,Sean M.J. McBride,Thomas A. Jongens +15 more
TL;DR: The results indicate that insulin misregulation underlies the circadian and cognitive phenotypes displayed by the Drosophila fragile X model, and thus reveal a metabolic pathway that can be targeted by new and already approved drugs to treat fragile X patients.